Eribulin mesylate in heavily pretreated metastatic breast cancer patients: Current practice in an Italian community hospital

Future Oncology

Volumn 10, Issue 2, 2014, Pages 233-239

  Poletti, Paola ^a   Ghilardi, Valentina ^a   Livraghi, Luca ^a   Milesi, Laura ^a   Rota Caremoli, Elena ^a   Tondini, Carlo ^a  

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

clinical benefit; community hospital; eribulin; metastatic breast cancer; microtubule inhibitor; monotherapy

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FURANS; HOSPITALS, COMMUNITY; HUMANS; ITALY; KETONES; MIDDLE AGED; NEOPLASM METASTASIS; RETREATMENT; TREATMENT OUTCOME;

EID: 84893872824     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.251     Document Type: Article

References (17)

1. Boyle P, Levin B. Breast cancer. In: World Cancer Report 2008. Boyle P, Levin B (Eds). International Agency for Research on Cancer, Lyon, France, 412-417 (2008).
2. Arriagada R, Spielmann M, Koscielny S et al. Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann. Oncol. 13(9), 1378-1386 (2002).
3. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl. 7), vii11-19 (2012).
4. Colozza M, De Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12(3), 253-270 (2007). (Pubitemid 46556792)
5. Pean E, Klaar S, Berglund EG et al. The European Medicines Agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin. Cancer Res. 18(17), 4491-4497 (2012).
6. Morris PG, Fornier MN. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev. Anticancer Ther. 9(2), 175-185 (2009).
7. Goel S, Mita AC, Mita M et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin. Cancer Res. 15(12), 4207-4212 (2009).
8. Tan AR, Rubin EH, Walton DC et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res. 15(12), 4213-4219 (2009).
9. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 27(18), 2954-2961 (2009).
10. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10(2), 160-163 (2010).
11. Aogi K, Iwata H, Masuda N et al. A Phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann. Oncol. 23(6), 1441-1448 (2012).
12. Donoghue M, Lemery SJ, Yuan W et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a 'physician's choice' control arm in a randomized approval trial. Clin. Cancer Res. 18(6), 1496-1505 (2012).
13. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 377(9769), 914-923 (2011).
14. Cortes J, Vahdat L, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28(25), 3922-3928 (2010).
15. Kaufman P, Awada A, Twelves C et al. A Phase III, open label, randomized, multicenter study of eribulin mesylate versus Capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at: 35th Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, USA, 4-8 December 2012.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
17. Panageas K, Ben-Porat L, Dickler M, Chapman P, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J. Natl Cancer Inst. 99(6), 428-432 (2007). (Pubitemid 47073565)